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Abstract
Background: Numerous studies have measured the prognostic associations between cardiorespiratory fitness and
patient outcomes in congenital heart disease, but no systematic review has assessed these associations for all types
of congenital heart disease. It is therefore a timely opportunity to syntheses all available data using a systematic
review methodology. The aim of this study is to detail the protocol for a systematic review and meta-analysis.
Objectives: Within this paper we have developed a protocol for a prognostic factors systematic review and meta-
analysis, to assess the role of cardiopulmonary exercise testing/cardiorespiratory fitness, in the prognosis of mortality
and morbidity in congenital heart disease.
Methods: We have outlined, in detail, the process for this systematic review using the latest accepted
methodological guidelines for prognostic factors research, such as the PICOTS system, CHARMS-PF data extraction,
QUIPS risk of bias assessments and the prognostic GRADE guidelines (see list of abbreviations).
Conclusion: The implications of this review will aid future treatments, interventions and individual patient risk
prediction. The publication of this protocol aims to improve scientific rigour by ensuring transparency in the
systematic review and meta-analysis process.
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Introduction
Congenital heart disease (ConHD) is a structural abnor-
mality of the heart or intrathoracic vessels [1], occurring
in approximately 1 % of all births worldwide [2, 3].
These defects are inclusive of a broad spectrum of over
18 different types of cardiac pathologies [4–6]. Long-
term survival is reduced in this patient population [7]
with repair status and severity of the lesion being risk
factors for excess mortality [8]. However, as a result of
improved medical care, survival over recent decades has
increased, leading to the highest proportion of ConHD
deaths now occurring in geriatrics [7, 9].
Cardiorespiratory fitness (CRF) is overall lower in pa-
tients with ConHD compared to healthy controls, it is
also highly heterogeneous both within and between indi-
vidual ConHD diagnoses, with the more severe condi-
tions presenting with lower levels of fitness [10]. This is
important as several studies have reported significant as-
sociations between CRF and mortality and morbidity in
ConHD [11–15].
Cardiopulmonary exercise testing (CPET) comprises a
known exercise stimulus with the simultaneous measure-
ment of pulmonary gas exchange, heart rate and blood
pressure. Analysis of CPET data can quantify various mea-
sures of CRF e.g., peak exercise capacity, physiological
thresholds, efficiency slopes and other physiological re-
sponses to the demands of the exercise stimulus [16]. It
has been recommended that CPET is used routinely in
the care of congenital heart disease patients in order to
evaluate and track disease severity [10].
While there has been a number of prognostic factor
studies on this topic, there has been no previous system-
atic review to synthesise all available data on cardiorespi-
ratory fitness and prognosis in congenital heart disease.
We aim to conduct this review to inform health care
policy and to highlight future avenues of research.
Objectives
This review will aim to assess the role of cardiopulmo-
nary exercise testing (CPET) in the prognosis of mortal-
ity and morbidity in individual congenital heart disease
lesions.
Methods
This protocol has been submitted in the international
prospective register of systematic reviews (PROSPERO;
CRD42020186518).
Types of participants
Any individual with a confirmed diagnosis of structural
ConHD will be included, regardless of severity, age, sex
and previous medical intervention. Exceptions include
patients who have a circulatory assist device in situ or
are post heart transplant, as they no longer reflect
ConHD physiology. We will also exclude patients with
cardiac diseases, such as acquired heart disease (valvular
and ischemic coronary disease), infective heart disease or
other types of inherited cardiac conditions (arrhythmia,
cardiomyopathy etc.). If mixed populations are reported
(e.g. cardiomyopathy separate to congenital heart disease
population), firstly we will consider subgroup analyses,
secondly contact the authors for data and if we cannot re-
solve inclusion by these steps, we will exclude the study if
ConHD is not represented in at least 70% of the sample.
Types of studies
We will include any study type that addresses the re-
search question (CPET & outcome), this will be inclusive
of, but not limited to cross-sectional and longitudinal
studies (prospective & retrospective). Individual case re-
ports, review papers, editorials and conference abstracts
with no subsequent peer reviewed full-text paper will be
excluded. We will exclude any paper that is not written
in English, unless provided with a translated manuscript
by the authors.
Methods of CPET and interpretation
Any treadmill and/or cycle ergometer protocol that dir-
ectly measures pulmonary gas exchange will be included.
Exclusion criteria include any exercise protocols that do
not directly measure gas exchange or fitness, such as the
6 min walk test. Expected parameters reported are max-
imal oxygen uptake (V̇O2 max), oxygen uptake efficiency
slope, ventilatory equivalents for carbon dioxide slope
(V̇E/V̇CO2 slope), exercise oscillatory ventilation and the
gas exchange threshold. Inclusion criteria will not be
limited to the expected parameters, any parameter that
can be collected or computed (e.g. blood pressure and
circulatory power) from a formal CPET shall be
reviewed as an ‘index prognostic factor’. We anticipate a
variety of different ‘comparator prognostic factors’ (co-
variates) to be reported, however, this will not form the
basis for our inclusion criteria.
Timing and setting
There will be no limits on timing and the setting of
prognostic factors (CPET results) within the review. The
timing of the CPET can be at any time point (pre/post-
operative or apart of routine follow up); traditionally
performed in a secondary or tertiary care provider.
Outcomes
Primary outcomes
 All-cause mortality or cardiac-related mortality
 Transplant or ventricular assist device
 Hospitalisation for a cardiac cause
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 Major Adverse Cardiovascular Event (composite of
cardiac death, transplant/ventricular assist device,
hospitalisation for cardiac cause).
The primary outcomes listed above will form the in-
clusion criteria for the review. Included studies will then
be checked to see if they contribute further data to our
secondary outcomes of interest.
Secondary outcomes
 Systolic and/or diastolic cardiac function
 Serious adverse events during CPET
 Cardiac intervention or re-intervention (surgical,
transcatheter or hybrid)
 Other morbidity (i.e. disease specific outcome)
Search methods
We will search the following bibliographic databases:
Allied and Complementary Medicine Database, CINA
HL® Complete and SPORTDiscus via EBSCO. Medline
and Embase will be searched via Ovid. We will also
search Web of Science (Thomson Reuters) and the
Cochrane Central Register of Controlled Trials.
We will also backward citation chase (search the refer-
ence list of relevant reviews and editorials), to find any
studies that may have been missed by the electronic
searches. We will also forward citation chase for any
paper that meets the inclusion criteria.
Our search terms will encompass prognosis (mortality,
morbidity, event free survival etc.) with congenital heart
disease (Fontan, Tetralogy of Fallot etc.) and CPET vari-
ables (maximal oxygen uptake V̇O2 max, Peak VO2, V̇E/
V̇CO2 slope etc.).The search strategy (Appendix) will be
adapted for use with the other bibliographic databases.
The search will be performed in July 2020, with no lower
limit for publication date. A repeat search will be per-
formed if screening, data analysis and publication re-
quires a period longer than 12months.
Data collection and analysis
After the deduplication of the searches, two independent
reviewers using Covidence® (Veritas Health Innovation
Ltd., Melbourne, Australia) will screen the titles and ab-
stracts. The full text of potentially eligible studies will be
retrieved and assessed for eligibility again independently
by two reviewers. Disagreements will be resolved by con-
sensus discussion, if the two review authors cannot re-
solve the disagreement, a third author will arbitrate. If
there are missing data we will contact authors for clarifi-
cation. We will include all studies that meet our inclu-
sion/exclusion criteria; record the process using the
Preferred reporting items for systematic review and
meta-analysis (PRISMA) guidelines, and present a PRIS
MA flow diagram and ‘Characteristics of excluded stud-
ies’ table [17, 18].
In order to extract data from the eligible studies, a
piloted form will be used. Data will be extracted by two
reviewers independently and discrepancies solved within
the review team. Where possible, missing data will be re-
quested from the study authors. The checklist ‘critical
appraisal and data extraction for systematic reviews of
prediction modelling and prognostic factors studies’
(CHARMS-PF) will be used for data extraction, as it fa-
cilitates comprehensive extraction of the following:
source of the data, participants, outcomes to be pre-
dicted, prognostic factors (types and timing), sample
size, missing data, analysis, results and interpretation
[19, 20]. Where studies have not optimally reported key
study data, such as the analysis method of their CPET
data, then we will contact the corresponding authors of
the text and ask for clarification.
Assessment of risk of bias
Two review authors will independently assess the quality
of the studies (risk of bias) using the Cochrane adopted
Quality in Prognosis Studies tool (QUIPS) [21]. This tool
supports a systematic appraisal of bias in studies, it in-
terrogates 6 domains of prognostic factor studies:
1. Study Participation
2. Study Attrition
3. Prognostic Factors
4. Outcome Measurement
5. Study Confounding and
6. Statistical analysis
Dealing with missing data
Where necessary we will contact authors or principle inves-
tigators to verify key study characteristics or obtain missing
data. If necessary we will convert medians and interquartile
ranges to means and standard deviations using a validated
Excel© calculator [22]. Furthermore, we will obtain un-
adjusted hazard ratios estimates where they have not been
reported, using established methods [23, 24].
Data synthesis
We will undertake meta-analyses only where this is
meaningful, i.e. if the participants, intervention, out-
comes and the underlying clinical question are similar
enough for pooling to yield interpretable results. If there
is sufficient data for meta-analyses to be undertaken, un-
adjusted (univariate) and adjusted (multivariate) esti-
mates will be analysed separately, in order to find a
‘genuine’ prognostic factor [20]. Where studies have
controlled for different covariates in the multivariate
analyses, we will transparently present what covariates
each study controlled for using footnotes. Furthermore,
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hazard ratios, odds ratios and risk ratios will also be
meta-analysed separately [20].
Following the recommendations of Riley and col-
leagues [20], we will pool data using a random-effects
meta-analysis due to the high probability of statistical
heterogeneity, which will be further explored using sub-
group analyses and meta-regression. However, we may
also report the fixed-effect pooled estimate and 95%
confidence interval only as a sensitivity analysis because
of the tendency of smaller trials, which are more suscep-
tible to publication bias, to be over-weighted with a
random-effects analysis.
We will also assess publication bias using visual in-
spection of funnel plots and the use of the Peter’s and
Debray’s tests for risk, odds and hazard ratios [25, 26].
We will provide a narrative synthesis of the findings,
there will be a section on each fitness parameter re-
ported (i.e., V̇O2 max) and its prognostic role in each in-
dividual congenital heart disease lesion. If the data are
available and sufficient, CPET variables will be combined
to provide appropriate prognostic ‘cut-offs’. If meta-
analysis is not undertaken we will follow the ‘Synthesis
without meta-analysis’ (SWiM) guidelines to ensure
transparency of our methods [27]. We will also use the
SWiM guidelines to enhance any written synthesis of
meta-analysed data.
Grades of recommendation assessment development and
evaluation (GRADE)
GRADE facilitates a standardised approach when asses-
sing the certainty of evidence, it is based on several do-
mains such as methodological limitations, inconsistency,
indirectness and impression [28]. Two review authors
will independently undertake GRADE, and where there
are discrepancies a third experienced author will arbi-
trate. Authors will follow the latest GRADE guidelines
for assessing evidence in prognostic factor studies by
Foroutan et al. [28]. Conducting GRADE should make
our findings more understandable to lay members such
as policy makers.
Subgroup analysis and investigation of heterogeneity
Each CPET variable reported will be a subgroup for the
analyses along with each individual type of ConHD le-
sion. If it is possible to pool ten or more studies in a
meta-analysis, we will explore heterogeneity using uni-
variate meta-regression in Stata©. Potential sources of
heterogeneity include:
 Age
 Percentage male/female
 Body mass index
 Percentage of population taking chronotropic
medication
 Year of study
 Location of study (continent)
 Severity of ConHD [Hoffman criteria [29]]
 Associated pulmonary pathology such as pulmonary
hypertension
 Sample size
 Length of follow up
 Risk of bias
 Number comparison prognostic factors
 Timing of the prognostic factors (routine care vs.
pre-operative etc.)
Sensitivity analysis
We will undertake sensitivity analyses comparing: ran-
dom effects vs. fixed effects meta-analysis and all studies
vs. exclusion of high risk of bias studies.
Conclusion
The publication of systematic review protocols increases
the transparency and robustness of the systematic review
process as any unplanned changes between the protocol
and the review will be explicit and will have to be justified.
This protocol for ‘the role of cardiopulmonary exercise
testing (CPET) in predicting mortality and morbidity in
people with congenital heart disease: a systematic review
and meta-analysis’ outlines our planned review and the ro-
bust systematic process that will be undertaken.
Appendix
Search strategy
Medline.
1# prognosis/ or exp. disease-free survival/.
2# (Prognosis or forecast or prospect or prediction or
projection or mortality or morbidity or transplant or
event free survival or hospitali?ation).ti,ab,kw.
3# exp. heart defects, congenital/ or exp. vascular mal-
formations/ or exp. heart valve diseases/ or exp. ven-
tricular outflow obstruction/ or exp. cardiovascular
abnormalities/.
4# (Congenital heart disease or Congenital heart dis-
eases or congenital heart defect or congenital heart or
ConHD or CHD or cyanotic heart disease or cyanotic
heart disease* or GUCH).ti,ab,kw.
5# (atrial septal defect or asd or septal defect or patent
ductus arteriosus or pda or bicuspid aortic valve or bav
or atresia or surgical repair or d-transposition or trans-
position great arteries or transposition of great arteries
or tga or crisscross heart* or mustard or arterial switch
or atrial switch or tetralogy of fallot or fontan or atrio-
pulmonary connection or intracardiac total cavopulmon-
ary connection or pulmonary atresia or absent
pulmonary valve or hypoplastic heart or hypoplastic
right heart or atresia or tricuspid atresia or pulmonary
atresia or Ebstein anomaly or hypoplastic left heart or
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aortic atresia or mitral atresia or single ventricle or sys-
temic right ventricle or sv or dorv or double outlet right
ventricle or truncus arteriosus or total anomalous pul-
monary venous connection or pulmonary stenosis or
double outlet left ventricle or acyanotic lesions or atrio-
ventricular septal defect or avsd or vsd or ventricular
septal defect or aortic stenosis or pulmonary stenosis or
coarctation or aortic incompetence).ti,ab,kw.
6# exp. exercise test/ or exp. physical endurance/ or
exp. anaerobic threshold/ or exp. exercise tolerance/ or
exp. physical fitness/ or exp. cardiorespiratory fitness/.
7# (Cardiopulmonary exercise test or CPET or Exer-
cise test or exercise tolerance test or fitness test or cycle
ergometry or treadmill ergometry or maximal oxygen
consumption or V̇O2 or VO2 max or VO2 peak or peak
VO2 or O2 pulse or ventilatory equivalent* or OUES or
oxygen uptake efficiency slope or petco2 or exercise os-
cillatory ventilation or oxygen uptake kinetics or end
tidal carbon or cardiorespiratory fitness or aerobic power
or exercise capacity or ventilatory threshold or VAT or
GET or gas exchange threshold or anaerobic thresh-
old).ti,ab,kw.
(#1 or #2 AND #3 or #4 or #5 AND #6 or #7)
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